ArticleChinese journal of integrative medicine2026
Berberine Ameliorates Angiotensin II-Induced Endothelial Dysfunction by Blocking AT1R, Inhibiting PDE4b and Activating AKT/eNOS Pathway.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic and Anti-Inflammatory Effects of Berberine-Rationale for Its Therapeutic Potential in Polycystic Ovary Syndrome.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether berberine (BBR) attenuates angiotensin II (Ang II)-induced endothelial dysfunction by antagonizing AT1R and modulating the phosphodiesterase 4b (PDE4b)-related signaling pathway.
methodsPrimary aortic endothelial cells were isolated and cultured from control and Ang II-induced hypertensive mice. Human umbilical vein endothelial cells (HUVECs), mouse aortic endothelial cells (MAECs) and ex vivo mouse aortae were treated with Ang II (1 µ mol/L), in the presence or absence of BBR, or the PDE4b inhibitor piclamilast. Quantitative real-time PCR (qPCR), Western blot, immunofluorescence, and microplate assays were employed to assess mRNA and protein expressions of PDE4b, Ang II type 1 receptor (AT1R), endothelial nitric oxide synthase (eNOS) and protein kinase B (PKB, as known as Akt) phosphorylation, and intra- and extracellular nitric oxide (NO) levels. Vascular ring assays were conducted to evaluate the endothelium-dependent relaxation (EDR) of isolated mouse aortae. In addition, molecular docking and cellular thermal shift assays were performed to investigate the interaction between BBR and the AT1R, with comparison to valsartan.
resultsAng II reduced eNOS phosphorylation and NO levels in HUVECs and impaired EDR in isolated mouse aortae (P<0.01), which were reversed by BBR co-treatment (P<0.05). BBR showed a binding free energy of -8.6 kCal/mol with AT1R and significantly enhanced AT1R thermal stability in 60, 65, 75 °C, exhibiting similar effects as valsartan in 60, 65, 75 °C (all P<0.05). Ang II upregulated PDE4b mRNA and protein levels in HUVECs and MAECs, while BBR reversed this effect in HUVECs (P<0.05 or P<0.01). Ang II also suppressed Akt phosphorylation in HUVECs, which was restored by BBR, like the effect of piclamilast (P<0.05 or P<0.01).
conclusionsBBR ameliorates Ang II-induced endothelial dysfunction primarily by antagonizing AT1R, suppressing PDE4b expression and restoring Akt/eNOS signaling. These findings provide mechanistic insights into BBR's endothelial-protective actions and highlight its therapeutic potential in treating hypertension-related vascular complications.
Indexed as
Identifiers
41838379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.